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triple negative breast carcinoma cells, MA B S T R A C T
Triple negative breast cancer (TNBC) is a very aggressive subgroup of breast carcinoma, still
lacking specific markers for an effective targeted therapy and with a poorer prognosis
compared to other breast cancer subtypes.
In this study we investigated the possibility that TNBC cells contribute to the establishment
of tumor vascular network by the process known as vasculogenic mimicry, through endo-
thelial cell differentiation.
Vascular-like functional properties of breast cancer cell lines were investigated in vitro by
tube formation assay and in vivo by confocal microscopy, immunofluorescence orase Free Survival; EGFR, Epidermal Growth Factor Receptor; ER, Estrogen Receptor; FFPE,
ibroblast Growth Factor Receptor; HER2, Human Epidermal Growth Factor receptor 2;
erived Growth Factor Receptor; PR, Progesterone Receptor; SRB, Sulforhodamine B; TEM,
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triple negative breast carcinoma cells, Mimmunohistochemistry on frozen tumor sections. TNBCs express endothelial markers and
acquire the ability to form vascular-like channels in vitro and in vivo, both in xenograft
models and in human specimens, generating blood lacunae surrounded by tumor cells.
Notably this feature is significantly associated with reduced disease free survival. The
impairment of the main pathways involved in vessel formation, by treatment with inhib-
itors (i.e. Sunitinib and Bevacizumab) or by siRNA-mediating silencing, allowed the identi-
fication of PDGFRb and FGFR2 as relevant players in this phenomenon. Inhibition of these
tyrosine kinase receptors negatively affects vascular lacunae formation and significantly
inhibits TNBC growth in vivo.
In summary, we demonstrated that TNBCs have the ability to form vascular-like channels
in vitro and to generate blood lacunae lined by tumor cells in vivo. Moreover, this feature is
associated with poor outcome, probably contributing to the aggressiveness of this breast
cancer subgroup. Finally, PDGFRb and FGFR2-mediated pathways, identified as relevant
in mediating this characteristic, potentially represent valid targets for a specific therapy
of this breast cancer subgroup.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction TNBCs are able to organize vessel-like networks throughTriple negative breast cancers (TNBCs) lack the threemost sig-
nificant therapeutic markers for clinical management of
breast cancer patients, Human Epidermal Growth Factor re-
ceptor 2 (HER2), Estrogen Receptor (ER) and Progesterone Re-
ceptor (PR) (Dawood et al., 2009; Irvin, Jr. and Carey, 2008),
and their prognosis is globally poorer than the other breast
carcinoma subgroups. Therefore, lacking specific markers
for an effective targeted therapy, TNBCs still represent the
most important challenge for clinical oncologists.
There is a significant molecular heterogeneity within TNBC,
which could explain the unsatisfactory activity of new therapies
utilizedso far inclinical trials.According to thefirst study report-
ing the intrinsic subclassification of breast carcinomas, where
gene expression profiles were able to further classify breast car-
cinomas in different subgroups, TNBCs mainly belong to basal-
like subtype (Perou et al., 2000). Successively, Cheang et al.
(2008) categorized TNBCs lacking basal Cytokeratin (CK) 5/6 and
Epidermal Growth Factor Receptor (EGFR) expression (5 negative
tumors), which actually account for about 50% of TNBCs. More
recently, molecular stratification of TNBCs primarily using
DNAmicroarrays and patterns of gene expression has identified
that TNBCs can be classified as basal-like (50%), claudin-low
(30%) and luminal A, B and HER2 subtypes for the remaining
20% distinct tumor subtypes (Perou, 2011; Prat and Perou, 2011).
Finally,a furthergeneprofilingofmorethan500TNBCsclassified
them in 6 different subtypes: basal 1 and 2, mesenchymal-like
and mesenchymal stem cell-like, immunomodulatory and
androgen pathway enriched (Lehmann et al., 2011).
Despite differences in molecular features, metastasis-free
survival analyses indicated that all TNBCs share a similar
poor prognosis among the different subtypes (Menard, 2011),
suggesting that aggressiveness of these tumors may account
for common characteristics. Supporting this hypothesis,
TNBCs are all enriched in expression ofmesenchymal/stromal
genes compared to luminal and HER2 breast cancer, feature
thatmight improve the crosstalk between tumor andmicroen-
vironment required for neoplastic progression. Moreover, it
has been recently suggested that aggressive tumors includingura, I., et al., PDGFRb an
olecular Oncology (2014trans-differentiative ability of cancer stem cells (Liu et al.,
2012). This process, called Vasculogenic Mimicry (VM), is prob-
ably able to provide nutrients to support TNBCs, contributing
to the disease progression with the acquisition of a more
aggressive and invasive phenotype (Kirschmann et al., 2012).
In this study, we deeply investigated the capability of
TNBCs to differentiate into endothelial cells and participate
in tumor vascularization. TNBC cells acquire indeed the ability
to form vascular-like channels both in vitro, when seeded on
Matrigel, and in vivo, generating blood lacunae lined by tumor
cells. Moreover, we identified Platelet-derived Growth Factor
Receptor b (PDGFRb) and Fibroblast Growth Factor Receptor
(FGFR) 2 pathways as relevant inmediating this characteristic,
potentially representing a valid target for a specific therapy of
this breast cancer group.2. Methods
2.1. Cell lines, reagents and treatments
All cell lines were purchased from ATCC (Rockville, MD, USA)
and maintained as recommended. MDA-MB-231-GFP cells
were kindly provided by Dr. Colombo (Fondazione IRCCS Isti-
tuto Nazionale dei Tumori, Milan).
SU11248/Sunitinib malate (Sutent) (Pzifer, New York, USA)
was resuspended inmethylcellulose and used at 40mg/kg/day
for 14 days (in vivo) or suspended in DMSO and used at 6.25 mM
(in vitro); Bevacizumab (Roche, Basel, Switzerland) was diluted
in physiological buffer and used in vivo (4 mg/kg/twice a week
for 4 weeks) and in vitro (50 mg/ml). TIMP-2 (MMP2 inhibitor)
(Chemicon International, Billerica, MA, USA) was used at
1 mg/ml, whereas Zometa (zoledronic acid, MMP9 inhibitor)
(Novartis, Basel, Switzerland) 5 mM in in vitro experiments.
Imatinib (Selleck Chemicals, USA) and pan-FGFR Inhibitor
(PD173074) were purchased from commercial suppliers, resus-
pended in DMSO and used at 10 mM (in vitro). All compounds
were used at a non-cytotoxic concentration (as evaluated by
Sulforhodamine B (SRB) colorimetric assay).d FGFR2mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
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with the same amount of vehicle.
2.2. Immunofluorescence analysis
When tumors reached a volume of about 150 mm3, mice were
injected i.v. with fluorescein Tomato lectin (VectorLabs, Bur-
lingame, CA, USA) or with Alexa Fluor 555Wheat Germ Agglu-
tinin (WGA) (Invitrogen Life Technologies, Carlsbad, CA) for
15 min and then animals were killed. Tumors were excised,
fixed with paraformaldehyde 4% and frozen processed.
Cryostat sections were permeabilized using PBS 0.1% Tri-
tonX100 and incubated with a blocking 2% BSA solution, pri-
mary antibodies, anti-EGFR rabbit (Acris Gmbh, Germany);
nuclear DRAQ-5 (Biostatus Limited, UK); biotinilated anti-
rabbit antibody, and finally detectedwithAlexa Fluor 546 Strep-
tavidin (InvitrogenMolecular Probes, Carlsbad, CA). Slideswere
analyzed with a confocal microscopy (Microradiance 2000; Bio-
Rad Laboratories) equipped with Argon/Krypton (488 nm),
HeNe (543 nm) and Red Laser Diode (638 nm) lasers. Confocal
images (512 512 pixels) were obtained using a 60 oil immer-
sion lens and analyzed using ImagePro 7.0 software. Reported
images represent a single frame from 15 to 16 stacks (0.5 mm
step). The pin-hole diameter was regulated according to the
value suggested by the acquisition software to obtain the
maximum resolution power.
2.3. Patient samples
Breast tissue samples obtained from patients with invasive
breast carcinoma were selected from the archives of the Hu-
man Pathology Section, University of Palermo and of the Pa-
thology Dept. of Fondazione IRCCS Istituto Nazionale dei
Tumori of Milan. 87 TNBC cases (of which 77 with available
follow-up), diagnosed between December 2007 and January
2012, according to immunohistochemical criteria (lack of ER,
PR and HER2 expression), were selected for this study. Thirty
specimen from luminal (20 cases) and HER2þ (10 cases) pa-
tients were selected as controls. All the TNBC cases could be
considered as grade 3 (G3) according to the Nottingham com-
bined histologic grade (Ellis and Elston, 2006). Non-TNBC
group comprised tumors with different histological features
and degree of pleiomorphism (8 cases of poorly differentiated
G3, 18 cases of moderately G2 and 4 cases of well differenti-
ated G1 tumors). All of the procedures were in accordance
with the Helsinki Declaration (World Medical Association,
2013). Concerning biospecimens, leftover material of samples
collected during standard surgical and medical approaches at
Fondazione IRCCS Istituto Nazionale dei Tumori of Milan are
used for research. Samples included in this paper have been
donated by the patients to the Institutional BioBank for
research purposes, and aliquots have been attributed to this
study after approval of Institutional Review Board and specific
request to the Independent Ethical Committee.
2.4. Histomorphological and immunohistochemical
analysis
Four-micrometers-thick sections of formalin-fixed and
paraffin embedded specimens were routinely-stained withPlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014Hematoxylin & Eosin for histomorphological evaluation. The
number of vascular lacunae, both in human andmurine sam-
ples, was assessed by counting the absolute number of
vascular structures lined by neoplastic cells out of 5 high-
power fields (HPFs, 400 magnification) and then averaging
the counts of the 5 fields. Similarly, in murine samples, the
average number of apoptotic figures out of the 5 HPF, was
also evaluated.
Immunohistochemistry was performed as previously re-
ported (Korpal et al., 2011). After microwave antigen retrieval,
the sections were incubated overnight with mouse anti-
human/mouse CD31 (dilution 1:50, Novocastra) primary anti-
bodies and staining was revealed by polymer detection kit
(Novocastra).
3,31-Diaminobenzidine (DAB; brown signal) was used as a
chromogenic substrate, and sections were counterstained
with Hematoxylin. Negative control stainings were performed
by using mouse, rabbit, or goat immune sera instead of the
primary antibodies.
For double-marker immunofluorescence on breast tissue,
sections underwent two sequential rounds of single-marker
immunostaining, as previously reported (Korpal et al., 2011).
The samples were incubated with mouse anti-human AE1/
AE3 pan-CK (dilution 1:100, Novocastra) or mouse/anti-hu-
man p53 (dilution 1:50, Novocastra), and, after Fc blocking,
withmouse anti-humanCD31 or CD34 (Novocastra). The bind-
ing was revealed using Alexa Fluor 488-conjugated and Alexa
Fluor 568-conjugated goat anti mouse antibodies (dilution
1:300, Invitrogen Life Technologies), respectively.
2.5. Electron microscopy
Tumors were immersion-fixed in 3% buffered glutaraldehyde
for 2 h, post-fixed in 1% osmium tetroxide and processed for
epoxy resin embedding and thin-sectioned.
2.6. In vitro tube formation assay
2  104 cells were seeded in 96-well plates pre-coated with
Matrigel (BD Biosciences) (35 ml/well, diluted 1:1 in medium
without FBS) and incubated for 4 h at 37 C. Tube formation
was acquired using a Nikon inverted light microscope (40),
and complete loops quantified by a macro made with the
Image-Pro Plus 7.0 software.
2.7. Knock-down of PDGFRb, FGFR2, FGFR1, VEGFR1,
VEGF and EGFR by siRNA transfection
siRNA for human PDGFRb, FGFR2, FGFR1, Vascular Endothelial
Growth Factor Receptor (VEGFR) 1, Vascular Endothelial
Growth Factor (VEGF) and EGFR (ON-TARGET plus SMART
pool, Dharmacon, Colorado, USA) or control siRNA (On-TAR-
GETplus Non-Targeting Pool) were trasfected (100 nM) using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells
were harvested at 24e48 h post-transfection.
2.8. SRB assay
5000 cells/well (MDA-MB-231, MDA-MB-468 and MCF-7) were
seeded in 96-well plates, treated with Sunitinib at differentd FGFR2 mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
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tions for 3 days, then processed as previously reported
(Skehan et al., 1990).2.9. Cell cycle
Cell cycle of 5 105 RNAi-silencedMDA-MB-231 andMDA-MB-
468 cells was evaluated as previously described (Di Leva et al.,
2010). The data obtained were analyzed using ModFit soft-
ware, 3.2 version (Verity Software House).2.10. Xenograft models
Experimental protocols were approved by the Ethics Commit-
tee for Animal Experimentation of Fondazione IRCCS Istituto
Nazionale dei tumori of Milan. Six-week-old female SCID
mice (Charles River, Wilmington, MA, USA) were given mam-
mary fat pad injections of 5  106 MDA-MB-231, MDA-MB-468
and MCF-7 cells diluted 1:1 in matrigel: RPMI 10% FBS (BD Bio-
sciences, Canada). Mice inoculated with estrogen-sensitive
MCF-7 cells were treated intramuscularly with weekly estra-
diol (0.12 mg/kg), starting 7 days before cell injection.
Tumor size was measured twice a week using digital cali-
pers. Mice were separated into four groups (n ¼ 7 mice/group):
when tumors reached a volume of 150mm3, theywere treated
or not with Sunitinib or Bevacizumab.2.11. Bio-Plex assay
Bio-Plex human assay (Bio-Rad Laboratories, Hercules, CA) for
simultaneous quantitation of the angiogenic factor VEGF, was
used according to themanufacturer’s instructions. Briefly, su-
pernatants of breast carcinoma cell lines seeded on plastic or
Matrigel for 4 h were incubated on properly 96-well plate with
polystyrene-beads coated with VEGF-specific antibodies, and
then exposed to detection antibodies prior incubation with
Streptavidin-PE. Capture lysates were analyzed on the Bio-
Plex 200 system (Bio-Rad). Data are presented as concentra-
tion (pg/mL). The concentration of analyte bound to each bead
is proportional to the median fluorescence intensity of re-
porter signal.2.12. Statistical analysis
For experiments analysis data were compared using Student’s
t-test and exact probability value for the relationship between
two dichotomous variables was calculated by Fisher’s exact
test using Graph Pad Prism 5 software (GraphPad software
Inc., San Diego, CA). All statistical tests were two-sided at
the conventional 5% significance level.
Disease Free Survival (DFS) cumulative incidence was
defined as the time elapsed from the date of surgery to the
date of the first event. DFS cumulative incidence curves
were drawn by the life-table method and the statistical signif-
icance tested by the log-rank test. The cut-off of Lacunae
numbers was fixed at 75th percentile according to a prelimi-
nary analysis carried out on quartiles.
Analysis were conducted using SAS software (SAS Institute
Inc., Cary, NC).Please cite this article in press as: Plantamura, I., et al., PDGFRb an
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3.1. TNBC cells acquire functional properties of
endothelial cells
Analysis of tube formation assay on Matrigel revealed
vascular channel formation in all six TN breast cancer cell
lines, representative of different molecular categories (MDA-
MB-468, HCC1937 and BT20 as basal-like; MDA-MB-231,
BT549 and MBA-MB-157 as mesenchymal-like), even though
only mesenchymal-like TNBC cells were able to form
completely closed loops, whereas no vascular structures
were generated by luminal or HER2-positive cells even at
longer times (up to 24 h) (Figure 1A).
To determine whether the phenomenon of VM observed
in vitro couldactually reflect apropertyofTNBCcellsalsopresent
in vivo, TN MDA-MB-231 or MDA-MB-468 and MCF-7 cells were
injected into mammary fat pad of SCIDmice. The evaluation of
formalin-fixed paraffin-embedded (FFPE) sections of engrafted
tumors with both MDA-MB-231 or MDA-MB-468 cell lines
revealed, particularly at the edge of infiltration, vascular lacunae
delimited by neoplastic cells with an elongatedmorphology and
nuclear features similar to those of neighboring, peri-vascular,
neoplastic cells (a representative example ofMDA-MB-231 xeno-
graft in Figure 1B, panels i and iii). Some of these lacunae were
filled with red blood cells and leukocytes, providing their func-
tional relationship with the systemic circulation. Consistently
with the acquisition of an endothelium-like phenotype, atypical
tumor cells liningvascular lacunaeshowed theexpressionof the
CD31marker,whichwashighlightedby immunohistochemistry
(Figure1B,panels ii and iv).Viceversa,MCF-7-derivedxenografts
lack vascular lacunae (Figure 1B, panels v and vii), showing
instead regular blood vessels exclusively composed of CD31þ
endothelial cells (Figure 1B, panels vi and viii).
The in vivo vasculogenic potential of TNBC xenografts was
also revealed by confocal analysis on frozen tumor sections of
TNMDA-MB-231-xenograftedmice injectedwithTomato lectin,
which allowed detection of vascular structures connected with
the systemic circulation. The presence of vascular structures
surrounded by MDA-MB-231 cells expressing the epithelial
marker EGFR confirmed the presence of functional vascular
lacunae delimited by tumor cells (Figure 2A). Moreover, these
data were further confirmed using xenograft models of MDA-
MB-231-GFP injectedwithAlexaFluor 555WGA:confocalmicro-
scopy analysis allowed a clear evaluation of the blood lacunae
surrounded by GFP positive tumor cells (Figure 2B).
In addition, channel-like structures formed by adjoining
tumor cells tightly encompassing erythrocytes in xenotrans-
planted tumors deriving from MDA-MB-231 cells were also
revealed by Transmission Electron Microscopy (TEM) analysis
(Suppl. Figure 1A, left panel). Differently from TNBC-derived
xenografts, tumor masses from MCF-7 engrafted mice lacked
vascular lacunae, whichwere replaced bywell-structured ves-
sels with recognizable lining endothelial cells (Suppl.
Figure 1A, right panel).
We thus investigated the formation of tumor vascular
lacunae in a series of 117 human breast cancer samples
including 30 non-TNBC (10 HER2 positive and 20 luminal)
and 87 TNBC. The morphological evaluation of TNBC andd FGFR2mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 1 e In vitro and in vivo VM. Tube formation capability was evaluated using a phase contrast light microscope (3100). Results are
representative of five independent experiments (A). Histopathological analysis of engrafted tumors with MDA-MB-231 and MCF-7 cells into
mammary fat pad of SCID mice demonstrate that only TNBC neoplastic cells directly participate in tumor vascularization. ieiv. Vascular
structures (lacunae) are generated in TNBCMDA-MB-231 xenografts. H&E staining (i, iii) shows the presence of nests (N) of atypical neoplastic
cells in TNBC along with blood lacunae surrounded by tumor cells (arrows). Immunohistochemical assays with the endothelial marker CD31 (ii,
iv) highlight that lacunae (asterisks) are composed of both endothelial and neoplastic cells (iv, inset). veviii. MCF-7 xenografts lack lacunae.
Tumors present a nested and trabecular (T) pattern (v, vii) and have regular blood vessels exclusively composed of endothelial cells (vi,viii, arrows).
Original magnification: i,ii,v,vi 3100; iii,iv,vii,viii 3200; inset 3400 (B).
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 4 5non-TNBC groups showed a different pattern of vasculature:
whereas the non-TNBC cases were mainly characterized by
a canonical peripheral and intratumoral vascular network,
composed by endothelial cell-lined vessels, TNBC cases
showed the formation of tumor vascular lacunae lined by
neoplastic cells with a pseudo-endothelial morphology and
characteristic nuclear atypia (Figure 3A). Such lacunae were
detected in 59 out of 87 (67.8%) TNBCs, 8 out of 20 (40%)
luminal cases and in 3 out of 10 (30%) HER2 cases, and their
number was assessed by counting the absolute number of
vascular structures lined by neoplastic cells out of 5 high-
power fields (HPFs,400magnification). Considering the cases
showing VM, the median of the absolute number of vascular
lacunae was significantly higher in TNBC cases groupPlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014compared to luminal ( p < 0.0001) or HER2 ( p ¼ 0.0055) group
(Suppl. Figure S2). Also TEM evidenced channel-like structures
delimited by tumor cells and containing erythrocytes in 3 out
of 5 TNBCs (an example is reported in Suppl. Figure 1B, left
panel) but not in the two luminal breast tumors tested
(Suppl. Figure S1B, right panel).
Double-immunofluorescent microscopy analysis of the
CD34 endothelial marker and AE1/AE3 pan-CK epithelial
marker highlighted the expression of CD34 in CKþ neoplastic
cells forming vascular structures in TNBCs. In non-TNBC
cases, CD34 and CK expression were not co-localized
(Figure 3B). This finding suggests the acquisition of an
endothelial-like phenotype, which impacts on both the
morphology and immuno-phenotype of TNBC cancer cells.d FGFR2 mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 1 e continued
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 46To further confirm the neoplastic epithelial origin of cells
lining vascular lacunae in TNBC cases, a double-marker
immunofluorescent analysis was performed using CD31 and
p53 specific antibodies. TNBCs are known to display mutated
p53 isoforms which are detectable by immunostaining. The
expression of p53 in CD31þ cells with elongated morphology
lining the lacunae of TNBCs clearly proved their neoplastic
clone derivation (Figure 3C).
Finally, to investigate the clinical impact of this biological
phenomenon, we analyzed the DFS of TNBCs stratifiedPlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014according to the number of vascular lacunae, and found that
thequartilewith thehighestnumberof lacunae ischaracterized
by poorest prognosis ( p ¼ 0.055) (Figure 4). The Kaplan-Meyer
curve showing all quartiles is reported in Suppl. Figure S3.
3.2. Pathways involved in endothelial-like behavior of
TNBC cells
To elucidate the mechanisms involved in VM, we investigated
the possible involvement of molecules previously reported tod FGFR2mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 2 e In vivo VM by confocal analysis. Images represent single frames of frozen tumor sections of tomato lectin-injected MDA-MB-231
xenograft mice and show an example of channel-like structures (green) delimited by tumor cells labeled with EGFR (red). Nuclei were stained with
DRAQ-5 (blue). Scale bars represent 10 mm (A). Images represent single frames of tumors deriving from MDA-MB-231-GFP xenograft mice
injected with Alexa Fluor 555 WGA and show blood lacunae (red) surrounded by GFP positive tumor cells (green). Nuclei were stained with
DRAQ-5 Scale bars represent 10 mm (B).
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 4 7be important in this phenomenon, asMMPs or EphA2 (Hendrix
et al., 2003; Kirschmann et al., 2012). However, neither treat-
ment with TIMP-2 (MMP2 inhibitor) or Zometa (MMP9 inhibi-
tor), at a concentration reported to be effective on VM
inhibition in tumor cells (Hess et al., 2003) (Moschetta et al.,
2010), or RNAi-mediated EphA2 silencing (data not shown)
produced any effect on the VM properties of our TN breast
cancer cell lines.
Therefore, to evaluate whether themain pathways physio-
logically implicated in vessel formation by endothelial cells
(i.e. VEGFR, PDFGR and/or FGFR) (Ferrara and Kerbel, 2005)
could be responsible for this phenomenon, we used twoPlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014different compounds, an antibody targeting VEGF (Bevacizu-
mab) and a tyrosin-kinase inhibitor targeting VEGFR, PDFGR,
FGFR (Sunitinib). We first verified that MDA-MB-231 cells ex-
press these receptors by Real-Time PCR (data not shown).
Moreover, we assessed by Bioplex the production and secre-
tion of VEGFA in the supernatant when cells are seeded in
matrigel, and observed that its level is significantly higher in
TN versus non-TN cell lines (Suppl. Figure S4).
Treatment with Sunitinib almost completely abrogated the
formation of vascular-like channels in vitro in TNBC cell lines,
whereas Bevacizumab did not show any inhibitory effect
(Figure 5A, representative VM images reported in left panelsd FGFR2 mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 3 e VM in human samples. Human TNBC samples showed the formation of tumor vascular lacunae lined by two different populations: one
comprised large neoplastic cells with a pseudo-endothelial elongated morphology and atypical nuclei (yellow arrows) and the other elongated
regular endothelial cells (blue arrows). The lacunae are filled by erythrocytes and leukocytes. Original magnification 3200 (left panel), 3400 (right
panel and inset) (A). Double-immunofluorescent microscopy analysis of the CD34 endothelial marker and AE1/AE3 pan-CK epithelial marker
highlighted the expression of CD34 in CKD neoplastic cells forming vascular structures in TNBCs. In non-TNBC cases, CD34 and CK
expression were not co-localized. Original magnification 3200 (B). A double-marker immunofluorescent analysis performed using CD31 and p53
specific antibodies revealed cells with elongated morphology lining the lacunae of TNBCs, further proving their neoplastic clone derivation.
Original magnification 3400 (C).
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 48andloopquantification intherightplot), suggestingthat thisphe-
nomenon is likely to be dependent on FGFR and PDGFR-induced
pathways and does not rely on the autocrine VEGF/VEGFR loop.
We then decided to define whether PDGFR and FGFRmedi-
ated pathways might also influence proliferation of TNBC
cells, in order to verify that VM inhibition was not related to
cell growth impairment: in vitro growth of TNBC cell lines
MDA-MB-231 and MDA-MB-468 and luminal MCF-7 treated
or not with Sunitinib or Bevacizumab was analyzed by SRB
assay. Growth of all tested cell lines was not affected by Bev-
acizumab treatment, whereas sensitivity of TNBC cell lines
to Sunitinib, evaluated calculating the IC50, was only slightly
higher compared with luminal cells (approximately 5e6 mM
in MDA-MB-468 and MDA-MB-231 cells, respectively, versus
10 mM in MCF-7 cells at 72 h; Suppl. Figure S5).
To determine whether the inhibition of PDGFR and FGFR
pathways had an impact on in vivo tumor growth, wePlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014evaluated the effect of Sunitinib and Bevacizumab in mouse
models of MDA-MB-231, MDA-MB-468 and MCF-7 cell lines.
MDA-MB-231 and MDA-MB-468 xenografts showed signifi-
cantly higher responsiveness to Sunitinib ( p < 0.001)
compared with Bevacizumab ( p < 0.05) (Figure 5B). Instead,
in luminal MCF-7-derived xenograft mice, treatment with
Sunitinib determined a tumor volume reduction comparable
to the effect obtained with Bevacizumab (Figure 5B). Histo-
morphological evaluation reported in Figure 6 and quantified
in Figure 5C showed that, even though also Bevacizumab
was able to exert a partial inhibitory effect, only treatment
with Sunitinib led to a statistically significant reduction in
the number of vascular structures comprising tumor cells in
TN xenograft mice ( p ¼ 0.0202 in MDA-MB-468; p ¼ 0.0020 in
MDA-MB-231).
However, since as above indicated Sunitinib is a multitar-
get agent, to better discriminate the contribution of thed FGFR2mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 4 e Kaplan-Meyer curve reporting DFS of 77 TNBCs divided
in two groups (one represented by the quartile characterized by the
highest number of lacunae, the other group including all 3 other
quartiles, which show a similar curve trend).
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 4 9different molecules affected by this TKI, we used two addi-
tional compounds with a more specific effect: PD173074, a
pan-FGFR inhibitor, and Imatinib, TKI against PDGFR. As ex-
pected, treatment with both compounds strongly inhibited
the capability to create vascular structures in vitro, recapitu-
lating Sunitinib effect, whereas single agent treatment only
partially affected the VM potential (Figure 7A, representative
images in the left panel and loop quantification in the right
plot), thus indicating that this property is likely to be depen-
dent on both FGFR and PDGFR-signaling pathways.
To further investigate this hypothesis, and to deeper
dissect themolecular pathways involved in this phenomenon,
we silenced single components of the relevant networks by
RNAi approach and evaluated the effect on VM. In detail, tran-
sient silencing of PDGFRb or FGFR2 significantly inhibited the
formation of channel structures of MDA-MB-231 cells,
whereas no effect was observed using siRNA against FGFR1,
EGFR or VEGFR1 (Figure 7B) and VEGF (7C), providing addi-
tional evidence of the marginal role of these pathways in
mediating VM. The efficient silencing of the molecules of in-
terest was evaluated by quantitative RT-PCR (Suppl.
Figure 6A), and evinced the possible existence of a crosstalk
between FGFR2 and PDGFRb, since even using single specific
siRNA oligonucleotides directed against one receptor, we
affected the expression of both.
Flow cytometric analysis of cell-cycle progression per-
formed after 24e48 h upon silencing showed approximately
20% decrease of S cell cycle phase inMDA-MB-231 cells treated
with PDGFRb (20%, p < 0.05) and FGFR2 (25%, p < 0.05) siRNAs.
Similar results were obtained using MDA-MB-468 cells (20%
with PDGFRb, p < 0.01; 25% with FGFR2, p < 0.05) (Suppl.
Figure 6B).
Since inhibitors targeting the single receptors (anti-FGFR
and Imatinib) produced a modest inhibitory effect on VM in
comparison with specific siRNAs (Figure 7A), we repeatedPlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014the treatment applying the same schedule used for siRNA
transfection. Pre-treatment for 24 h with single inhibitors
(Imatinib or anti-FGFR) significantly impaired VM potential
of MDA-MB-231 cells (Suppl. Figure 7A, and quantified in right
panel). As expected, impairment of FGFR and PDGFR pathways
led to reduced expression of the other receptor (PDGFRb and
FGFR2, respectively), whereas no reduction was observed at
short time (4 h) (Suppl. Figure 7B).4. Discussion
Our study has highlighted the ability of TNBC cells to directly
contribute to tumor vasculature by endothelial cell differenti-
ation, a capability which recapitulates the plasticity of embry-
onic mesodermal progenitor cells performing the
vasculogenic process in order to provide blood supply. Indeed,
VM probably serves as a selective advantage to rapidly
growing tumors by providing a perfusion pathway which con-
tributes to the disease progression with the acquisition of a
more aggressive and invasive phenotype. This hypothesis is
supported by the evidence that, within the TNBC subgroup,
a higher number of vascular lacunae is significantly associ-
ated with reduced DFS.
Even though the presence of vascular lacunae also in HER2
positive and luminal specimens might suggest that this phe-
nomenon is not unique of TNBC, however it is certainly
more common and peculiar, since it is present in a signifi-
cantly higher percentage of cases and with a higher number
of structures.
The correlation between VM and an undifferentiated
phenotype reminiscent of embryologic events has been
confirmed by the ability of cancer stem cells to perform this
phenomenon (Ricci-Vitiani et al., 2010), and very recently by
the association with the expression of stemness marker
CD133 in TNBC (Liu et al., 2012). At a functional point of
view, our study demonstrates that a crucial role in mediating
vasculogenic properties of TNBC is exerted by PDGFRb and
FGFR2 mediated pathways. Indeed, even though tested TNBC
models do not present amplification or overexpression of
these molecules, their inhibition strongly impairs the capa-
bility to form channel-like structures, thus suggesting the
involvement of these pathways in the observed phenomenon.
It has been reported that MDA-MB-231 mainly express the
beta isoform of PDGFR (Weigel et al., 2009) and the FGFR2 IIIc
isoform, associated with a more mesenchymal and undiffer-
entiated phenotype (Cha et al., 2009; Luqmani et al., 1996).
Amplification of FGFR2 has been reported in a percentage of
TNBCs and associated with poor prognosis (Dey et al., 2010),
and PDGFRb inhibition has been shown to impair the estab-
lishment of experimental bone (Farmer et al., 2005; Skehan
et al., 1990) or lung (Jechlinger et al., 2006) metastases from
breast cancer cells.
Even though we cannot completely exclude possible off
targets effects of a multi-target TKI as Sunitinib, the concen-
trations we used in our in vitro assays are consistent with pre-
vious reports, as a very recentwork by Hollier et al. (2013), who
used this compound to inhibit FOXC2-induced PDGFRb. More-
over, the impairment of VM upon specific RNAi-mediatedd FGFR2 mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 5 e In vitro and in vivo effect of Sunitinib and Bevacizumab and quantification of “blood lacunae”. Cells were seeded in 96-well tissue
culture plates pre-coated with Matrigel and treated with Bevacizumab or Sunitinib (A); the assay was quantified as percentage of loops formation
compared to untreated cells (right panel). Each value represents the mean ± s.d. of data from three separate experiments. 5 3 106 TN MDA-MB-
231, MDA-MB-468 or luminal MCF-7 cells were injected into mammary fat pad of SCID mice, and when tumors reached a volume of 150 mm3,
mice were treated or not with Sunitinib ( per os, 40 mg/kg/day for 14 days) or Bevacizumab (i.p., 4 mg/kg twice at week for 4 weeks). Xenograft
tumors derived from MDA-MB-231 and MDA-MB-468 cells showed highly significant responsiveness (***p< 0.001) to Sunitinib in comparison
with MCF-7 xenografts (*p< 0.05). Treatment with Bevacizumab caused comparable effects in terms of tumor volume reduction in MDA-MB-
231, MDA-MB-468 and in MCF7-derived xenograft mice. Error bars represent SD of 7 mice per group (B). Quantification of the absolute number
of vascular structures lined by neoplastic cells out of 5 high-power fields in sections from untreated, Sunitinib- or Bevacizumab-treated MDA-
MB-231 (left Scattered dot plot) or MDA-MB-468 (right Scattered dot plot) (*p[ 0.0202, ***p[ 0.0020) evaluated in four different mice (line at
median value) (C).
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 410silencing of the receptors clearly demonstrates their involve-
ment in this phenomenon.
Notably, the evidence that, even though we used very
specific siRNA oligos, the silencing of FGFR2 partially
affected also the expression of PDGFRb, and vice versa, sug-
gests the existence of a functional crosstalk, as already sug-
gested in literature (Nissen et al., 2007). Moreover, the effect
of 24 h pre-treatment with single inhibitors (Imatinib and
anti-FGFR) on VM potential and on the expression of the
other receptor (FGFR2 and PDGFRb, respectively) furtherPlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014supports this hypothesis, and underlines that PDGFRb and
FGFR2 are probably both required in sustaining VM
phenomenon.
Besides the in vitro studies, results of Sunitinib treatment in
TN xenografts indicate that TN cancer cells, coherently with
their endothelial features, strongly rely on PDGFRb and
FGFR2-dependent pathways for their fitness and survival, as
suggested by the impressive TN tumor growth inhibition par-
alleled by a conspicuous impairment of TN tumor vasculo-
genic potential.d FGFR2mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 6 e In vivo vascular lacunae. Differential density of vascular lacunae (black arrows) in untreated (upper panels), Bevacizumab (middle
panels) and Sunitinib (lower panels) treated engrafted tumors. While control cases showed the higher presence of vascular lacunae, their number
progressively decreases in Bevacizumab treated mice. Sunitinib treatment exerted the strongest effects by inducing the decrease of vascular lacunae.
Focal areas of necrosis (N) could be detected in both Bevacizumab- or Sunitinib treated mice. Original magnification 3100 left panels, 3200 right
panels.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 4 11Even though it has been reported that inhibition of VEGF
reduces angiogenesis and growth of TN MDA-MB-231-
derived xenografts (Roland et al., 2009), in our hands the effect
in terms of volume reduction mediated by Bevacizumab was
definitelyweaker than Sunitinib and comparable to the inhibi-
tion observed in luminal MCF-7-derived xenograft tumors.
Surprisingly, and despite it does not affect VM in vitro, also
Bevacizumab partially reduced the number of vascular
lacunae, even though to a lesser extent and with no statistical
significance: this capability might account for the slight but
still significant reduction in xenograft tumor growth upon
Ab treatment, and underlines how the in vivo setting can
reveal mechanisms that we can underestimate by in vitro ex-
periments. However, considering the strongest and statisti-
cally significant effect of Sunitinib in this phenomenon, we
can certainly hypothesize that Bevacizumab is likely to act
mainly on “standard angiogenesis”, characterized by the pres-
ence of endothelium-surrounded blood vessels, whereas
Sunitinib may target the pathways triggering the ability of tu-
mor cells to behave as endothelial cells.
It cannot be excluded that these pathways are also
involved in the proliferation or survival of TNBC cells, howev-
er the slight different sensitivity to Sunitinib showed by TNBC
cells in comparison with our luminal model in vitro definitely
cannot account for the impressive tumor growth inhibition
observed in vivo only in TN-derived xenograft mice. Moreover,Please cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014the evidence that the conspicuous inhibition of the vasculo-
genic potential upon Sunitinib treatment of TN xenografts
was not paralleled by a significant induction of cancer cell
apoptosis (data not shown) further supports the hypothesis
that these pathways aremainly responsible of driving the vas-
culogenic properties of TNBC, and that TN tumor growth inhi-
bition is mainly due to the impairment of this phenomenon.
Moreover, it is also worth reporting that, when we per-
formed VM assay, cells on matrigel were exposed to the drug
for a very short period of time (4 h), and theminimum concen-
tration we found to almost completely abrogate tube forma-
tion did not affect cell viability, thus excluding that the
inhibitory effect in performing vascular structures might be
due to cell suffering or proliferation arrest. Finally, evaluation
of cell cycle progression of MDA-MB-231 and MDA-MB-
468 cells at 24e48 h upon RNAi-mediated silencing of PDFGRb
and FGFR2 showed a statistically significant but not impres-
sive reduction in the percentage of S phase cells.
Despite the more efficient capability to perform VM in vitro
showed by mesenchymal cell lines, our in vivo data show that
both basal-like (MDA-MB-468) and mesenchymal-like (MDA-
MB-231) TNBC cells contribute to tumor vascularization, and
that Sunitinib strongly inhibits tumor growth of both TN
models, thus indicating that inhibition of pathways involved
in TNBC vasculature might represent an effective common
therapy in this BC subtype. This aspect is extremelyd FGFR2 mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
Figure 7 e In vitro effect of pan-FGFR inhibitor and Imatinib and siRNAs. Cells were seeded in 96-well tissue culture plates pre-coated with
Matrigel and treated with pan-FGFR inhibitor or Imatinib or both (10 uM each one) (A) for 4 h; for silencing experiments, cells previously
transfected with specific siRNAs for 24e48 h were tested for VM for 4 h (B and C). The assay was quantified as percentage of loops formation
compared to untreated cells. Each value represents the mean ± s.d. of data from three separate experiments.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 412important, considering that the high molecular heterogeneity
of TNBC, currently well recognized, has not been clearly eluci-
dated yet.
However, the clinical application of Sunitinib is certainly
limited by its relevant toxicity. Moreover, whereas Dey et al.
(2010) reports that long term treatment with TKI258, targetingPlease cite this article in press as: Plantamura, I., et al., PDGFRb an
triple negative breast carcinoma cells, Molecular Oncology (2014the same receptors inhibited by Sunitinib, induces both pri-
mary tumor growth and lung metastases reduction in a
model of mammary carcinoma, two recent papers underline
how short term treatment with anti-angiogenic drugs as
Sunitinib reduces the volume of the primary tumor but in-
creases the number of metastasis in breast cancer (Ebosd FGFR2mediate endothelial cell differentiation capability of
), http://dx.doi.org/10.1016/j.molonc.2014.03.015
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 4 13et al., 2009), glioma and pancreatic cancer (Paez-Ribes et al.,
2009). Our preliminary data also suggest an increase in the
number of lung metastases upon Sunitinib treatment (data
not shown).
The reason might rely on side effects on the tumor envi-
ronment, probably mediating hypoxia andmobilitating tumor
cells to intra-vasate, and/or producing a severe vessel unbal-
ance that facilitates extravasation and colonization at the
metastatic site. This evidence, even though still controversial,
limited to mouse models, and yet to be supported by a biolog-
ical explanation, rises however a clearly important issue.
Considering the strong inhibitory effects on tube formation
in vitro that we obtained silencing each single receptor, an
alternative, or probably even more efficient, approach to a
multitarget TKI as Sunitinib could be represented by an
RNAi-mediated therapy. However, it is of extreme importance
to verify whether the silencing of these receptors is able to
reduce the primary tumor growth without dangerously
increasing the number of metastases (on going).5. Conclusions
TNBC cells have the ability to form vascular-like channels
both in vitro, when seeded on Matrigel, and in vivo, generating
blood lacunae lined by tumor cells. This peculiar endothelial
behavior of TNBC, indicating an extremely undifferentiated
phenotype, significant cell plasticity and the possibility to
actively participate in providing blood supply, seems to
contribute to the aggressiveness of this breast cancer sub-
group, since a higher number of vascular structures is associ-
ated with poorer prognosis. Moreover, PDGFRb- and FGFR2-
mediated pathways, identified as relevant in mediating this
characteristic, potentially represent valid targets for a specific
therapy of this breast cancer group.Competing interests
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